Health & Environmental Research Online (HERO)


Print Feedback Export to File
8246158 
Journal Article 
Practical considerations in the use of maprotiline (Ludiomil) in general practice 
Lloyd, AH 
1977 
Yes 
Journal of International Medical Research
ISSN: 0300-0605
EISSN: 1473-2300 
5 
suppl. 4 
122-138 
English 
Meprotiline (Ludiomil) is an impressive tetracyclic drug with both sedative, tranquillizing and antidepressant effects which are all directly proportional to dosage. There are negligible effects on the cardiovascular system in man and it does not influence the central metabolism of 5HT. Maprotiline has shown itself to be a broad spectrum antidepressant and its use is indicated in the treatment of all types of depression. It is more rapid in its onset of action than tricyclic antidepressants, therapeutic response being produced in a few days, and is only slowly eliminated. It has been found to produce a minimum of side-effects, such as drowsiness and dry mouth. Its toxicity in accidental or suicidal overdosage is similar to that of the tricyclics, but is less in severity. It may be used in glaucoma, urinary and prostatic patients or in patients with moderate or severe respiratory problems. Post-coronary maprotiline treatment is contra-indicated in this country but has been used with success when depression interfered with patient recovery. Maprotiline has significant anti-aggressive properties and may, therefore, prove to be of inestimable value in the treatment of aggressive teenagers who are a notably difficult fraction of our society to treat. Maprotiline has been used in behavioural disorders of children including enuresis. Maprotiline also exhibits an anabolic effect and this may well be used to advantage in the underweight, anorexic and possibly in the post-convalescent patient. Maprotiline has been shown to be of great benefit in menopausal depression, in endogenous types of depression, in the elderly and in failed suicidal patients.